This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up
by Zacks Equity Research
Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.
Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates
by Zacks Equity Research
Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.
Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.
Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine
by Zacks Equity Research
Amgen (AMGN) beats estimates for earnings and sales in the second quarter. Higher demand for new growth drivers was offset by the erosion of mature brands from brand/biosimilar competition.
Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.
Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up
by Zacks Equity Research
Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.
Economic and Earnings Date Deluge
by Zacks Equity Research
Economic and Earnings Date Deluge
Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More
by Mark Vickery
Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.
Eli Lilly (LLY) Tops Q2 Earnings Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 2.74% and -0.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats estimates for second-quarter earnings. Key immunology drug Dupixent drives sales. The company ups its earnings growth expectations for the year.
What's in Store for Array BioPharma (ARRY) in Q4 Earnings?
by Zacks Equity Research
Array BioPharma's (ARRY) Braftovi-Mektovi combination therapy is likely to drive fourth-quarter sales.
Should You Buy Eli Lilly (LLY) Ahead of Earnings?
by Zacks Equity Research
Eli Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment
by Kinjel Shah
AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.
Eli Lilly (LLY) Stock Down 6.8% in 2019: Can Q2 Earnings Boost Performance?
by Mitchell Moore
Eli Lilly and Company (LLY) stock is down 6.8% YTD, slightly worse than a large-cap pharma average of -5.4%. Let's dive into Eli Lilly and see what to expect from its results heading into its Q2 earnings report that will be released before the market opens on Tuesday, July 30.
Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.
Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
NuCana Initiates Dosing in Phase I Study for Solid Tumors
by Zacks Equity Research
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
AC Immune Initiates Phase I Study for Alzheimer's Disease
by Zacks Equity Research
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA
by Zacks Equity Research
Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.
Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
by Zacks Equity Research
Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.
4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
by Christopher Vargas
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.